MedinCell announces the availability of its 2021/2022 Universal Registration Document including the Annual Financial Report 

MedinCell (FR0004065605 – MEDCL), a pharmaceutical company at premarketing stage developing a portfolio of long-acting injectable products in various therapeutic areas, announces today the filing of its 2021/2022 Universal Registration Document (URD) with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference D.22-0662.
The universal registration document notably includes:
• the annual financial report for the year ending on March 31, 2022;
• the management report;
• the CSR report;
• the report on corporate governance; and
• the proposed text of the resolutions to be submitted to the ordinary and extraordinary Shareholders’ Meeting of September 8, 2022.
This universal registration document may be consulted on the Company’s website (invest.medincell.com), “Investors” section, and on the AMF’s website (www.amf-france.org).